Myotonic Dystrophy Type II - DM2 (ZNF9)

Stanford University is collecting samples of blood, muscle and other tissues from people with neuromuscular disorders for use in research

posted on January 7, 2015 - 12:06pm
Ever wondered how someone with a neuromuscular disorder in his or her family might contribute to research efforts in this field?

Small molecules that induce or reverse effects of the type 1 myotonic dystrophy mutation in cells in the lab are likely to speed research

posted on July 9, 2013 - 11:01am
Matthew Disney is a current and former MDA grantee at the Scripps Research Institute in Jupiter, Fla. Disney's current MDA grant is focused on targeting toxic RNA in type 2 myotonic dystrophy (MMD2, or DM2).

Located around the United States, MDA’s new network provides a foundation for the conduct of clinical trials in MMD1 and MMD2

posted on January 23, 2013 - 10:00am
MDA has launched a new, five-center clinical research network focused on type 1 and type 2 myotonic muscular dystrophy (MMD1 and MMD2, also known as DM1 and DM2), with the principal goal of preparing for testing of new MMD treatments as they become available.

Two companies will jointly develop a drug for type 1 myotonic dystrophy; UK survey responders say modafinil's benefits for MMD1-related sleepiness outweigh side effects

posted on July 11, 2012 - 6:00am
Type 1 myotonic dystrophy (MMD1, or DM1) and type 2 myotonic dystrophy (MMD2, or DM2) are complex, multisystem disorders caused by similar genetic flaws on chromosome 19 (MMD1) and chromosome 3 (MMD2). Treatments that target the underlying molecular causes of MMD1 and MMD2 are in development.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
The complex and multifaceted disease known as myotonic muscular dystrophy (MMD) — also known as dystrophia myotonia (DM) — was the subject of an In Focus report in the April-June 2012 Quest. Here, we delve into experimental strategies that may markedly improve the outlook for people with this disorder.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
Thomas Cooper, a professor in the Department of Pathology and Immunology at Baylor College of Medicine, is a longtime MDA research grantee who has current MDA support to develop oligonucleotide-based therapies for myotonic muscular dystrophy (MMD, also known as DM). Margaret Wahl, MDA's medical and science editor, talked with Cooper about his research.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
Matthew Disney is an associate professor in the Department of Chemistry at the Scripps Research Institute in Jupiter, Fla. He has MDA support to design small molecules that target the toxic RNA that underlies myotonic muscular dystrophy (MMD, also known as DM). MDA Medical and Science Editor Margaret Wahl talked with Matthew Disney about his work.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
Charles Thornton, a professor of neurology at the University of Rochester (N.Y.), has received MDA support for research in myotonic muscular dystrophy (MMD, also known as DM) and other neuromuscular diseases. He's currently developing antisense oligonucleotides and small molecules for MMD. Thornton also co-directs the MDA clinic and directs the MDA/ALS Center at the University of Rochester...